Bill
Bill > HR2374
US HR2374
US HR2374Stop STALLING Act Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
summary
Introduced
04/29/2019
04/29/2019
In Committee
04/30/2019
04/30/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A BILL To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition and facilitate the efficient review of petitions filed in good faith to raise legitimate public heath concerns, and for other purposes. HR 2374 RH 1
AI Summary
This bill, known as the Stop STALLING Act (Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act), aims to empower the Federal Trade Commission (FTC) to deter the filing of sham citizen petitions that attempt to interfere with the approval of competing generic drugs or biosimilars. The bill defines a "sham petition" as one that is objectively baseless and aims to use the governmental process to hinder a competitor's business. The bill establishes that submitting or causing the submission of such sham petitions is an unfair method of competition, allowing the FTC to pursue civil actions and penalties against offenders. The bill also includes provisions to facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns.
Committee Categories
Justice
Sponsors (8)
Hakeem Jeffries (D)*,
David Cicilline (D),
Steve Cohen (D),
Doug Collins (R),
Jerry Nadler (D),
Bill Posey (R),
F. James Sensenbrenner (R),
Peter Welch (D),
Last Action
Placed on the Union Calendar, Calendar No. 577. (on 12/24/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...